1-{4-[6-(2,6-dimethyl-phenyl)-quinazolin-2-ylamino]-phenyl}-3-(2-pyrrolidin-1-yl-ethyl)-imidazolidin-2-one | 1234096-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-{4-[6-(2,6-dimethyl-phenyl)-quinazolin-2-ylamino]-phenyl}-3-(2-pyrrolidin-1-yl-ethyl)-imidazolidin-2-one
• 英文别名: 1-[4-[[6-(2,6-Dimethylphenyl)quinazolin-2-yl]amino]phenyl]-3-(2-pyrrolidin-1-ylethyl)imidazolidin-2-one
• CAS: 1234096-28-6
• 化学式: C₃₁H₃₄N₆O
• 分子量: 506.651
• InChiKey: TYRDPAITJGOXCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] SUBSTITUTED QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS QUINAZOLINE SUBSTITUÉS
  申请人：FOVEA PHARMACEUTICALS SA

  公开号：WO2010076238A1

  公开（公告）日：2010-07-08

  The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

  本发明涉及某些新颖化合物、生产它们的方法以及治疗或改善激酶介导的疾病的方法。更具体地说，本发明涉及取代喹唑啉化合物，其可用作选择性激酶抑制剂，生产这种化合物的方法以及治疗或改善激酶介导的疾病的方法。特别是，这些方法涉及治疗或改善激酶介导的疾病，包括心血管疾病、糖尿病、与糖尿病相关的疾病、炎症性疾病、免疫性疾病、癌症和眼部疾病，如视网膜病变、黄斑退化或其他玻璃体视网膜疾病等。
• SUBSTITUTED QUINAZOLINE COMPOUNDS
  申请人：Fovea Pharmaceuticals

  公开号：EP2381943A1

  公开（公告）日：2011-11-02
• US8389530B2
  申请人：——

  公开号：US8389530B2

  公开（公告）日：2013-03-05